Company Information

  

Address: 50 TICE BOULEVARD, SUITE 315  
City: WOODCLIFF LAKE 
State: NJ 
Zip Code: 07677 
Telephone: 201-326-5300 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company registered at and with principal offices at 50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey 07677. On November 16, 2016, we purchased all of the outstanding capital stock of Arsia Therapeutics, Inc. ("Arsia"), and subsequently changed its name to Eagle Biologics, Inc. ("Eagle Biologics"). Business Our business model is to develop proprietary innovations to FDA-approved, injectable drugs, that offer commercial and/or functional advantages to currently available alternatives. We have historically been, and will continue to primarily be, focused on developing and commercializing injectable drugs, primarily in the critical care and oncology areas, using the United States Food and Drug Administration ("FDA")'s 505(b)(2) New Drug Application ("NDA") regulatory pathway.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/20175.92NA13.33
03/20176.44NA12.88
12/20164.96NA16.00
09/20161.54NA45.45
06/20160.17NA228.18
03/2016-1.21NAN/E
12/20150.16NA554.19
06/2015-0.70NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity0.46Total Liab/Total Assets0.29
Net Inc/Total Assets0.38Total Liab/Inv Cap0.36
Net Inc/Inv Cap0.47Total Liab/Comm Equity0.36
Pretax Inc/Net Sales0.28Interest Coverage Ratio6679.38
Net Inc/Net Sales0.43Curr Debt/EquityNA
Cash Flow/Net Sales0.28LTD/EquityNA
SG&A/NetSales0.28Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover5.54Quick Ratio2.60
Inventory Turnover6.22Current Ratio2.66
Inventory Day Sales0.06Net Rec/Curr Assets0.39
Net Sales/Work Cap2.78Inv/Curr Assets0.03
Net Sales/PP&E57.14  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 50.11 76.79 81.14 37.83
Cost of Goods Sold 13.82 17.99 18.82 10.43
Selling & Admin Exps 23.70 18.58 17.39 10.81
Operating Income 5.90 32.70 28.29 12.31
Interest Exp 0.04 0.03 0.00 0.00
Pretax Income 5.88 32.67 28.29 12.33
Other Income 0.01 0.00 0.01 0.03
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 4.50 22.92 57.30 11.95

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 55.39 27.71 52.82 59.31
Receivables - Total 53.23 84.74 42.19 47.05
Inventories - Total 3.59 3.02 2.74 7.11
Total Current Assets 123.87 123.57 109.11 119.05
Net Property, Plant & Equipment 3.77 3.80 3.32 2.83
Total Assets 220.18 224.82 214.32 146.73
Liabilities        
Accounts Payable 30.83 34.43 39.95 34.44
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 31.95 35.44 40.97 35.45
Long-Term Debt NA NA NA NA
Total Liabilities 54.82 57.99 63.09 41.20
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.02 0.02 0.02 0.02
Retained Earnings 1.77 -2.74 -25.66 -82.96
Treasury Stock -62.31 -50.66 -37.00 -18.00
Total Stockholders' Equity 165.36 166.83 151.23 105.52
Total Liabilities and Stockholders' Equity 220.18 224.82 214.32 146.73

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities 37.55 -12.44 39.56 13.17
Net Cash Provided by Investing Activities -0.21 -0.68 -27.62 -14.18
Net Cash Provided by Financing Activities -9.67 -12.00 -18.43 -15.24

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201313.68-6.05--
12/201419.10-17.98-0.92
12/20145.60-5.51-0.92
12/201566.232.570.16
12/2016189.4881.454.96
Growth Rates92.92----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1718420,393--




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.